Pharmacokinetics of the Antineoplastic Drug Mitomycin C in Regional Chemotherapy Using the Aortic Stop Flow Technique in Advanced Pancreatic Carcinoma

Chemotherapy ◽  
2005 ◽  
Vol 51 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Frank Meyer ◽  
Karsten Ridwelski ◽  
Thomas Gebauer ◽  
Reinhard Grote ◽  
Jens Martens-Lobenhoffer ◽  
...  
Keyword(s):  
Pancreatic Carcinoma ◽  
Mitomycin C ◽  
Regional Chemotherapy ◽  
Antineoplastic Drug ◽  
Advanced Pancreatic Carcinoma ◽  
Stop Flow

Results of Regional Chemotherapy Using the Aortic Stop-Flow Technique in Advanced Pancreatic Carcinoma

Surgery Today ◽  
2006 ◽  
Vol 36 (2) ◽  
pp. 155-161 ◽  
Author(s):  
Frank Meyer ◽  
Thomas Gebauer ◽  
Reinhard Grote ◽  
Jens Martens-Lobenhoffer ◽  
Karsten Ridwelski ◽  
...  
Keyword(s):  
Pancreatic Carcinoma ◽  
Regional Chemotherapy ◽  
Advanced Pancreatic Carcinoma ◽  
Stop Flow

scholarly journals A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity

2003 ◽  
Vol 14 (7) ◽  
pp. 1100-1105 ◽  
Author(s):  
R.D. Petty ◽  
M.C. Nicolson ◽  
S. Skaria ◽  
T.S. Sinclair ◽  
L.M. Samuel ◽  
...  
Keyword(s):  
Pancreatic Carcinoma ◽  
Mitomycin C ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Low Toxicity ◽  
Advanced Pancreatic Carcinoma

Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group.

1986 ◽  
Vol 4 (12) ◽  
pp. 1794-1798 ◽  
Keyword(s):  
Pancreatic Carcinoma ◽  
Mitomycin C ◽  
Therapeutic Benefit ◽  
Gastrointestinal Tumor ◽  
Tumor Study ◽  
Phase Ii Studies ◽  
Gastrointestinal Tumor Study Group ◽  
Advanced Pancreatic Carcinoma ◽  
Advanced Pancreatic Adenocarcinoma ◽  
Toxic Reactions

One hundred thirty-three patients with advanced pancreatic adenocarcinoma and measurable disease were treated with 5-fluorouracil (5-FU) plus doxorubicin plus mitomycin C (FAM), streptozotocin plus mitomycin C plus 5-FU (SMF) in the regimen originally reported, and streptozotocin plus mitomycin C plus 5-FU with 5-FU and streptozotocin administered in five-day courses. Respective response rates for all patients were 13%, 15%, and 14%, and for previously untreated patients, 14%, 14%, and 15%. Median survivals for all previously untreated patients range from 3 months (FAM) to 4 1/2 months (original SMF). Predominant toxic reactions were vomiting, leukopenia, and thrombocytopenia. Without evidence of greater therapeutic benefit, none of these regimens should be used in the routine treatment of advanced pancreatic carcinoma.

Paclitaxel as weekly second-line therapy in patients with advanced pancreatic carcinoma

2000 ◽  
Vol 11 (8) ◽  
pp. 635-638 ◽  
Author(s):  
Helmut Oettle ◽  
Dirk Arnold ◽  
Martin Esser ◽  
Dieter Huhn ◽  
Hanno Riess
Keyword(s):  
Pancreatic Carcinoma ◽  
Second Line ◽  
Second Line Therapy ◽  
Line Therapy ◽  
Advanced Pancreatic Carcinoma

Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma

2005 ◽  
Vol 76 (1) ◽  
pp. 48-53 ◽  
Author(s):  
Morten Hoyer ◽  
Henrik Roed ◽  
Lisa Sengelov ◽  
Anders Traberg ◽  
Lars Ohlhuis ◽  
...  
Keyword(s):  
Pancreatic Carcinoma ◽  
Phase Ii ◽  
Stereotactic Radiotherapy ◽  
Phase Ii Study ◽  
Locally Advanced ◽  
Locally Advanced Pancreatic Carcinoma ◽  
Advanced Pancreatic Carcinoma
Sign in / Sign up

Export Citation Format

Share Document